Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Carter

Showing results (801-810 of 872) with videos related to

Pageof 88
Sort By:
Journal of Virology|October 19, 2018
Multiple Introductions and Antigenic Mismatch with Vaccines May Contribute to Increased Predominance of G12P[8] Rotaviruses in the United StatesKristen M Ogden, Yi Tan, Asmik Akopov, et al.
Bioorganic & Medicinal Chemistry Letters|August 3, 2020
Discovery of (3S,4S)-3-methyl-3-(4-fluorophenyl)-4-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxyprop-2-yl)phenyl)pyrrolidines as novel RORγt inverse agonistsBin Jiang, James J-W Duan, Sylwia Stachura, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2010
IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studyGuido Marcucci, Kati Maharry, Yue-Zhong Wu, et al.
ACS Medicinal Chemistry Letters|July 21, 2015
Dimeric Macrocyclic Antagonists of Inhibitor of Apoptosis Proteins for the Treatment of CancerYong Zhang, Benjamin A Seigal, Nicholas K Terrett, et al.
Blood|October 28, 2011
ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic categoryKlaus H Metzeler, Heiko Becker, Kati Maharry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2012
Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemiaGuido Marcucci, Klaus H Metzeler, Sebastian Schwind, et al.
Blood|May 6, 2010
Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studyHeiko Becker, Guido Marcucci, Kati Maharry, et al.
Parkinsonism & Related Disorders|December 2, 2015
Interprofessional education increases knowledge, promotes team building, and changes practice in the care of Parkinson's diseaseElaine V Cohen, Ruth Hagestuen, Gladys González-Ramos, et al.
Leukemia|December 12, 2013
GAS6 expression identifies high-risk adult AML patients: potential implications for therapySusan P Whitman, Jessica Kohlschmidt, Kati Maharry, et al.
ACS Medicinal Chemistry Letters|April 21, 2015
Discovery of a Potent and Orally Bioavailable Dual Antagonist of CC Chemokine Receptors 2 and 5Percy H Carter, Gregory D Brown, Robert J Cherney, et al.
Pageof 88

Showing results (801-810 of 872) with videos related to

Sort By:
Pageof 88
Journal of Virology|October 19, 2018
Multiple Introductions and Antigenic Mismatch with Vaccines May Contribute to Increased Predominance of G12P[8] Rotaviruses in the United StatesKristen M Ogden, Yi Tan, Asmik Akopov, et al.
Bioorganic & Medicinal Chemistry Letters|August 3, 2020
Discovery of (3S,4S)-3-methyl-3-(4-fluorophenyl)-4-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxyprop-2-yl)phenyl)pyrrolidines as novel RORγt inverse agonistsBin Jiang, James J-W Duan, Sylwia Stachura, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2010
IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studyGuido Marcucci, Kati Maharry, Yue-Zhong Wu, et al.
ACS Medicinal Chemistry Letters|July 21, 2015
Dimeric Macrocyclic Antagonists of Inhibitor of Apoptosis Proteins for the Treatment of CancerYong Zhang, Benjamin A Seigal, Nicholas K Terrett, et al.
Blood|October 28, 2011
ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic categoryKlaus H Metzeler, Heiko Becker, Kati Maharry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2012
Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemiaGuido Marcucci, Klaus H Metzeler, Sebastian Schwind, et al.
Blood|May 6, 2010
Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studyHeiko Becker, Guido Marcucci, Kati Maharry, et al.
Parkinsonism & Related Disorders|December 2, 2015
Interprofessional education increases knowledge, promotes team building, and changes practice in the care of Parkinson's diseaseElaine V Cohen, Ruth Hagestuen, Gladys González-Ramos, et al.
Leukemia|December 12, 2013
GAS6 expression identifies high-risk adult AML patients: potential implications for therapySusan P Whitman, Jessica Kohlschmidt, Kati Maharry, et al.
ACS Medicinal Chemistry Letters|April 21, 2015
Discovery of a Potent and Orally Bioavailable Dual Antagonist of CC Chemokine Receptors 2 and 5Percy H Carter, Gregory D Brown, Robert J Cherney, et al.
Pageof 88